Welcome to our store
When researchers receive a chemical, peptide, biological material, or other research compound, one of the first questions is simple:
What exactly is this material, and does it meet the expected specifications?
A Certificate of Analysis, commonly abbreviated as COA, is one of the documents used to communicate analytical results for a particular batch or lot of material.
A COA can contain information such as the material name, batch number, test methods, specifications, analytical results, and release information.
However, a COA should not be treated as a magic guarantee of quality.
Understanding what the document actually says—and what it does not say—is an important part of evaluating research materials.
FDA guidance and enforcement materials emphasize the importance of testing materials for attributes such as identity, strength, quality, and purity, and FDA has specifically discussed the need to establish the reliability of supplier-provided COAs when they are used in quality systems. (U.S. Food and Drug Administration)
In this guide, we’ll explain what a COA is, what information it may contain, how batch documentation works, and what researchers should consider when reviewing analytical results.
A Certificate of Analysis is a document that reports analytical testing or quality information associated with a particular material or batch.
Depending on the material and testing program, a COA may include:
The exact format can vary considerably between laboratories, manufacturers, suppliers, and industries.
For active pharmaceutical ingredients, FDA’s ICH Q7 guidance describes COAs as including information such as the material name, batch number, release date, tests performed, acceptance limits, and numerical results where applicable. (U.S. Food and Drug Administration)
That makes the COA more than just a piece of paperwork.
It can provide a documented record of how a particular batch was evaluated against defined specifications.
A research material is not necessarily identical to every other batch made under the same product name.
Manufacturing processes, raw materials, equipment, storage conditions, and other variables can affect individual batches.
This is why batch or lot numbers are important.
A batch number allows a laboratory or quality team to connect a specific material to its associated manufacturing and testing records.
For example:
Compound: Example Peptide
Batch: ABC123
Test: Purity
Specification: ≥ 95%
Result: 98.2%
The result relates to the identified batch—not automatically to every batch of that compound ever produced.
This distinction is particularly important when reviewing research materials.
There isn’t one universal COA format, but several pieces of information are particularly useful.
The document should clearly identify what material was tested.
This may include:
The identity information should correspond to the material being evaluated.
A mismatch between a container label and its documentation is a reason for additional investigation rather than an assumption that everything is correct.
The batch number connects the analytical report to a specific production lot.
This is one of the most important pieces of information on a COA.
If a laboratory receives material labeled with one batch number but the COA identifies another batch, the documents should not simply be treated as interchangeable.
Batch traceability allows quality teams to connect:
Material → Batch → Testing → Documentation
This helps maintain a record of what was tested and what was actually received.
A COA may include a specification or acceptance criterion.
For example, a hypothetical document might state:
| Test | Specification | Result |
|---|---|---|
| Identity | Conforms | Pass |
| Purity | ≥ 95% | 98.4% |
| Appearance | White powder | Conforms |
The specification tells you what result is considered acceptable under that particular testing program.
The result tells you what was actually measured.
These two columns should be considered together.
Identity testing asks a fundamental question:
Is this material what it is supposed to be?
Identity testing can involve different analytical techniques depending on the compound.
FDA materials describe analytical testing for characteristics including identity, strength, potency, purity, and composition. (U.S. Food and Drug Administration)
For some pharmaceutical research materials, techniques such as spectroscopy or chromatography may contribute to identity characterization.
FDA’s current chemistry, manufacturing, and controls guidance for investigational drugs gives examples including Nuclear Magnetic Resonance (NMR), infrared spectroscopy, ultraviolet spectroscopy, and High Performance Liquid Chromatography (HPLC) as analytical approaches that can support identity or purity information, depending on the substance and purpose of the testing. (U.S. Food and Drug Administration)
The exact method should therefore be considered in context.
Purity generally describes how much of the analyzed material corresponds to the intended substance relative to detected impurities or other components, according to a defined analytical method.
For example, imagine a hypothetical analytical result:
Purity: 98.5%
That number can look straightforward, but it should not be interpreted without understanding how the purity was measured.
Different analytical methods can answer different questions.
A chromatographic purity result, for example, may describe the proportion of detected components under a particular method.
It does not necessarily mean that the material is “98.5% perfect” in every possible sense.
This is an important distinction when reading laboratory documentation.
These two concepts are related but different.
Imagine a hypothetical sample that contains a large amount of a particular chemical.
A purity test might indicate a high percentage of one component.
But researchers still need to know whether that component is actually the intended compound.
This is why identity and purity are separate analytical concepts.
In quality systems, both can be important.
A useful way to think about it is:
Identity:
“What is this material?”
Purity:
“How much of the measured material corresponds to the intended component under this analytical method?”
Strength/assay:
“How much active substance is present according to the applicable analytical method?”
The exact terminology and testing approach can vary by material and application.
High Performance Liquid Chromatography (HPLC) is an analytical technique widely used to separate and analyze components in a mixture.
In research and pharmaceutical analysis, chromatography can help laboratories examine a sample and identify or quantify components based on how they behave under defined analytical conditions.
For some materials, HPLC may be used to estimate purity or assay.
However, HPLC is not a single universal test with one fixed meaning.
The method, column, mobile phase, detection system, reference standards, calculations, and acceptance criteria all matter.
Therefore, when reading a COA, don’t focus only on a percentage.
Look for the method and specification behind that percentage.
Mass spectrometry (MS) is another analytical technique used to investigate molecules according to their mass-to-charge characteristics.
For some compounds, mass spectrometry can provide useful information supporting molecular identity.
In peptide research, mass spectrometry may be used as part of analytical characterization.
Again, the important point is context.
A laboratory report should ideally make clear what was tested, what method was used, and what conclusion the reported result supports.
One analytical technique rarely answers every possible quality question.
You may see statements such as:
Pass
Conforms
Meets Specification
or
Complies
These terms generally indicate that the reported result met the stated acceptance criteria.
But you should still examine the actual specification.
For example:
Purity specification: ≥ 95%
Result: 97.8%
Status: Pass
The result can be understood relative to the stated specification.
However, if a COA only says “Pass” without explaining the test, method, specification, or result, it provides less analytical detail to the reader.
This is why the complete document is generally more informative than a simple statement that a product “passed testing.”
A number on a COA has meaning only in relation to the method used to produce it.
Consider a hypothetical purity result:
99% purity
A useful reviewer would ask:
The answers provide context.
FDA’s CMC guidance emphasizes analytical methods and acceptable limits for identity, strength, quality, and purity when describing investigational drug substances and products. (U.S. Food and Drug Administration)
This is an important quality-control question.
A supplier’s COA can provide useful information, but a COA is not necessarily a substitute for an organization’s entire quality system.
FDA has repeatedly emphasized this point in its inspection and enforcement materials.
For example, FDA has cited manufacturers for relying on supplier COAs without adequately establishing the reliability of supplier testing and without performing required identity testing on incoming components. (U.S. Food and Drug Administration)
The broader principle is straightforward:
Documentation should be supported by an appropriate quality-control process.
The exact requirements depend on the material, product, industry, applicable regulations, and intended use.
COA verification involves evaluating whether the information supplied on a certificate can be relied upon.
A quality system may consider factors such as:
USP materials similarly describe supplier qualification and periodic comparison of supplier COA results with testing as components of a quality approach for pharmaceutical ingredients. (USP)
The objective is not simply to collect documents.
The objective is to have reasonable evidence that the documented results accurately represent the material being received.
In regulated pharmaceutical manufacturing, testing may be performed before a batch is released.
The purpose is to determine whether the batch conforms to established specifications.
FDA describes release testing as an important quality safeguard and has emphasized testing for attributes such as identity, strength, quality, and purity. (U.S. Food and Drug Administration)
The exact testing requirements vary depending on the product and regulatory framework.
For sterile products, additional quality attributes can be especially important.
FDA’s investigational-drug CMC guidance, for example, notes that injectable products may require consideration of sterility, pyrogenicity/endotoxin levels, and particulate matter. (U.S. Food and Drug Administration)
A COA can provide valuable analytical information, but it does not necessarily answer every question about a research material.
For example, a COA may not establish:
This distinction is especially important for research peptides and experimental compounds.
Analytical quality and clinical effectiveness are different questions.
A laboratory can determine that a material meets a defined purity specification without that result proving that the compound is medically effective.
This distinction connects directly with our article:
A COA answers questions primarily related to the material being tested.
A scientific study answers questions about a research question or biological effect.
For example:
COA:
“What material was analyzed, and what were the reported analytical results?”
Research study:
“What happened when researchers tested the compound under specific experimental conditions?”
These are complementary types of information.
A high-quality research study still needs accurate information about the material being investigated.
Likewise, a detailed COA does not automatically establish that the material has a particular biological or clinical effect.
When reviewing a Certificate of Analysis, start with these questions:
Check the name, product code, and other identifying information.
Compare the COA with the physical material or container documentation.
Look beyond a simple “pass” statement.
Understand what acceptance criteria were applied.
Numerical results can provide more information than a simple pass/fail statement.
The method helps explain what the reported result means.
Look for laboratory or manufacturer information where appropriate.
Check dates, batch numbers, signatures or authorization, and other quality records.
Analytical results should always be interpreted according to the purpose of the material.
Here is a fictional example for educational purposes:
| Attribute | Specification | Result | Status |
|---|---|---|---|
| Identity | Conforms | Conforms | Pass |
| Purity | ≥95% | 98.3% | Pass |
| Appearance | White powder | White powder | Pass |
| Water content | ≤5% | 2.1% | Pass |
This example illustrates the basic structure of analytical reporting.
Notice that the specification and result appear together.
The result is meaningful because it can be compared with a predefined criterion.
A real COA may contain substantially more information, including analytical methods, reference standards, laboratory details, dates, chromatograms, or other supporting documentation.
Good documentation allows a laboratory to trace a material through its quality records.
For example:
Supplier
↓
Material received
↓
Batch/Lot number
↓
Sampling
↓
Analytical testing
↓
Results
↓
Quality review
↓
Research use or disposition
This type of traceability can make it easier to investigate discrepancies or unexpected results.
If a research result looks unusual, knowing exactly which batch of material was used can become important.
Reliable research depends on more than the experimental design itself.
Researchers also need to understand what materials were used and how those materials were characterized.
Documentation such as COAs can contribute to that process.
For pharmaceutical development, FDA’s CGMP information emphasizes quality systems, appropriate raw materials, reliable laboratory testing, procedures, and investigation of quality deviations. (U.S. Food and Drug Administration)
This reflects a broader scientific principle:
Good research requires good records.
When material identity, batch information, analytical methods, and results are documented clearly, researchers have a stronger foundation for interpreting experimental work.
A Certificate of Analysis is a document reporting analytical testing or quality information associated with a particular material or batch.
The documentation requirements depend on the material, organization, study, applicable regulations, and quality system. A COA is commonly used to document analytical information, but the exact requirements vary.
No. A COA generally documents specified analytical results. It does not by itself establish clinical safety.
No. Purity and biological effectiveness are different questions.
No. A COA is an analytical or quality document. It does not establish FDA approval or marketing authorization.
It connects the analytical results to a specific lot of material and supports traceability.
A COA can provide useful information, but quality systems may require evaluation and verification of supplier testing. FDA has specifically cited inadequate reliance on supplier COAs without appropriate verification. (U.S. Food and Drug Administration)
A Certificate of Analysis is an important piece of documentation for understanding the analytical characteristics of a research material.
When reviewing a COA, don’t focus only on a single purity number.
Look at the compound identity, batch number, specifications, analytical methods, actual results, laboratory information, and traceability.
It is also important to understand what a COA cannot establish.
A COA can provide information about the material that was tested, but it does not automatically prove clinical effectiveness, medical suitability, or regulatory approval.
For research compounds and peptides, these distinctions are especially important.
A useful approach is to consider three separate questions:
1. What is the material?
Identity and characterization.
2. Does the material meet its analytical specifications?
Purity, assay, quality attributes, and other applicable tests.
3. What does scientific research tell us about the material?
Laboratory studies, animal research, human trials, and replicated evidence.
Keeping these questions separate makes scientific information easier to understand and helps prevent laboratory quality data from being confused with clinical or regulatory conclusions.
© 2026 All rights reserved
